Evidence map›Paper›PMID 39656778›Full record

ArticleChemMedChem2025

Discovery of Novel Pyrido[2,3-b]Pyrazine Human Cytomegalovirus Polymerase Inhibitors with Broad Spectrum Antiherpetic Activity and Reduced hERG Inhibition.

Bing Bai, Appan Srinivas Kandadai, Mostofa Hena, Alexandr Belovodskiy, John Shen, Michael Houghton, James A Nieman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Harnessing cuproptosis: a new avenue for targeted cancer therapies.Apoptosis : an international journal on programmed cell death · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bing BaiLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0000-0003-4102-305X
Appan Srinivas KandadaiLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0009-0000-1806-510X
Mostofa HenaLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0009-0007-8764-9863
Alexandr BelovodskiyLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0000-0002-4944-8469
John ShenProFoldin, 10 Technology Drive, Suite 40, Hudson, MA 01749-2791, USA.
Michael HoughtonLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0000-0003-3762-6771
James A NiemanLi Ka Shing Applied Virology Institute, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.ORCID https://orcid.org/0000-0002-5087-0819

Funding

Li Ka Shing Applied Virology Institute RES0055738
6 · The paper itself

Abstract

The development of non-nucleoside inhibitors targeting human cytomegalovirus (HCMV) polymerase presents a promising approach for enhancing therapeutic treatment for patients with sustained HCMV viremia. A series of non-nucleoside HCMV DNA polymerase inhibitors with various substitution groups at 2-postition of the novel pyrido[2,3-b]pyrazine core was synthesized and investigated. The study focused on optimizing HCMV polymerase inhibition while minimizing off-target inhibition of human ether-à-go-go (hERG) ion channel. Several compounds exhibited strong antiviral activity against HCMV (typical EC

Indexed as

Antiviral AgentsCytomegalovirusPyrazinesDNA-Directed DNA PolymeraseDose-Response Relationship, DrugDrug DiscoveryEther-A-Go-Go Potassium ChannelsHumansMicrobial Sensitivity TestsMolecular StructureStructure-Activity RelationshipAntiviral AgentsDNA-Directed DNA PolymeraseEther-A-Go-Go Potassium ChannelsPyrazinesDNA polymerase inhibitorshERG inhibitionHuman cytomegalovirus (HCMV)Non-nucleosidePyrido[2,3-b]pyrazine

Identifiers

PMID39656778
PMCPMC11911297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.